Indivior PLC (INDV)

32.97

-0.57 (-1.70%)

Inactive · Last trade price on Jan 23, 2026

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Development, Manufacture and Sale of Buprenorphine-Based Prescription Drugs	1.19B	1.09B	901.00M	791.00M	647.00M
Development, Manufacture and Sale of Buprenorphine-Based Prescription Drugs Growth	8.69%	21.31%	13.91%	22.26%	-17.58%
Total	1.19B	1.09B	901.00M	791.00M	647.00M
Total Growth	8.69%	21.31%	13.91%	22.26%	-17.58%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
United States	1.01B	912.00M	732.00M	603.00M	456.00M
United States Growth	10.53%	24.59%	21.39%	32.24%	-22.58%
Rest of World	179.00M	181.00M	169.00M	181.00M	182.00M
Rest of World Growth	-1.10%	7.10%	-6.63%	-0.55%	-3.70%
United Kingdom	-	-	-	7.00M	9.00M
United Kingdom Growth	-	-	-	-22.22%	28.57%
Total	1.19B	1.09B	901.00M	791.00M	647.00M
Total Growth	8.60%	21.31%	13.91%	22.26%	-17.58%

Source: S&P Global Market Intelligence.